This trial is active, not recruiting.

Condition hemophilia a
Sponsor CancerCare Manitoba
Collaborator The Hospital for Sick Children
Start date September 2014
End date December 2015
Trial size 42 participants
Trial identifier NCT02225483, H2013:304


The is study will examine whether variation in clinical bleeding frequency and severity among boys with severe Hemophilia A (Factor VIII deficiency) is associated with variations in laboratory measurements of platelet activity.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case control
Time perspective prospective
Boys with Factor VIII coagulant activity less than or equal to 1%.

Primary Outcomes

Procoagulant platelet-derived microparticle formation
time frame: At time of enrollment
Platelet aggregation
time frame: At time of enrollment

Eligibility Criteria

Male participants from 3 years up to 20 years old.

Inclusion Criteria: - documented circulating FVIII level of ≤1% - age 3 - 20 years - may be on primary or secondary prophylaxis - granting of informed consent Exclusion Criteria: - measurable inhibitor level at the time of enrollment - ingestion of aspirin/supplement known to influence platelet function within 14 days of blood sampling, or ibuprofen within 3 days

Additional Information

Official title Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function
Trial information was received from ClinicalTrials.gov and was last updated in January 2016.
Information provided to ClinicalTrials.gov by CancerCare Manitoba.